Showing 3851-3860 of 7133 results for "".
- Researchers ID Genetic Risk Factors for Early-Onset Merkel Cell Carcinomahttps://practicaldermatology.com/news/researchers-id-genetic-risk-factors-in-early-onset-mcc/2462201/New research indicates that germline variants in genes are significantly associated with early-onset Merkel cell carcinoma (MCC). The case-control study included 1,012 individuals (37 of whom had early-onset MCC, 45 with later-onset MCC, and 930 controls) who were prospectively enrolled
- Interim Analysis Shows Dupilumab Safe, Effective for AD Treatment at 2 Yearshttps://practicaldermatology.com/news/real-world-effectiveness-of-dupilumab-in-adult-and-adolescent-patients-with-atopic-dermatitis-2-year-interim-data-from-the-prose-registry/2462202/Dupilumab was associated with improved disease control in patients with moderate-to-severe atopic dermatitis (AD) at two years, according to a new interim analysis. The study, published in Dermatology and Therapy, examined two-year data from the PROSE AD Registry (an ongoing, pros
- Upadacitinib Linked with Improvement for Hand Eczema in Patients with Atopic Dermatitishttps://practicaldermatology.com/news/updacitinib-shows-promise-for-ad-and-hand-eczema-in-trial/2462198/Results from a new study suggest that upadacitinib is efficacious for the treatment of hand eczema (HE) and atopic dermatitis (AD) in patients with AD. The study authors, publishing in Contact Dermatitis, included a total of 38 patients in the observational cohort analysis (32 of
- Lower Extremity Lymphedema Linked with Increased Risk for Skin Cancerhttps://practicaldermatology.com/news/lower-extremity-lymphedema-linked-with-increased-risk-for-skin-cancer/2462193/New research suggests that patients with lower extremity lymphedema are at an increased risk for skin cancer. Researchers writing in Mayo Clinic Proceedings enrolled more than 4,400
- PF-07038124 Shows Safety, Efficacy for AD and Plaque Psoriasis: Studyhttps://practicaldermatology.com/news/efficacy-and-safety-of-pf-07038124-in-patients-with-atopic-dermatitis-and-plaque-psoriasis/2462191/A novel topical phosphodiesterase 4 inhibitor (PF-07038124) has been shown to be efficacious and well-tolerated in patients with atopic dermatitis (AD) and plaque psoriasis, according to new study results. Researchers writing in
- Birch Triterpenes Topical Gel Gets FDA Approval for Treatment of Epidermolysis Bullosahttps://practicaldermatology.com/news/birch-triterpenes-topical-gel-gets-fda-approval-for-treatment-of-epidermolysis-bullosa/2462190/Chiesi Global Rare Diseases announced today that the FDA had approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB) in patients 6 months or older. According
- Lindus Health and Thirty Madison Complete Enrollment of Personalized Dermatology Care Pilot Studyhttps://practicaldermatology.com/news/lindus-health-and-thirty-madison-complete-enrollment-of-personalized-dermatology-care-pilot-study/2462182/Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialized healthcare brands, announced the completion of enrolment of a pilot study to assess the effectiveness of their personalized dermatology telemedicine platform Facet. The novel teleh
- Intradermal AIV001 Found Safe in Early BCC Studyhttps://practicaldermatology.com/news/intradermal-aiv001-found-safe-in-early-bcc-study/2462178/AiViva Biopharma Inc. completed its first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma (BCC) tumors. AIV001 is intradermally administered and designed for local, prolonged treatment effect for dermatological conditions. The phase
- Revealed: How Chronological Aging Affects EV Production by Human Keratinocyteshttps://practicaldermatology.com/news/revealed-how-chronological-aging-affects-ev-production-by-human-keratinocytes/2462166/Aging modulates extracellular vesicles of epidermal keratinocytes, new research in Aging suggests. The disturbance of intercellular communication is one of the hallmarks of aging. In their new study, researchers from
- AD Pipeline Watch: Escient Pharmaceuticals Initiates Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonisthttps://practicaldermatology.com/news/ad-pipeline-watch-escient-pharmaceuticals-initiates-proof-of-concept-study-of-ep262-a-first-in-class-oral-mrgprx2-antagonist/2462155/The first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of Escient Pharmaceuticals’ EP262 in atopic dermatitis (AD). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell medi